Advocacy
Your
Say...
Life sciences experts speak their
minds on UK industry strategy *
“At the BIA [BioIndustry
Association], we’ve extended
our focus beyond Brexit to
include strong input into the
industrial strategy for
life sciences.”
Dr Kevin Cox, CEO of Imanova,
Member of the BIA Board
“There has been a massive escalation in the regulations since the single
market in 1992 and 1995 and now I feel we function under Directives and
GVP modules. We have a network of pharmacovigilance where the UK is
a major player and the objective has actually moved from the movement
of goods to enhancing public health by good scientific collaborations.”
Professor Saad Shakir, Director, Drug Safety Research Unit (DSRU)
* Unless otherwise dated, quotations are based on the transcript from the March 2017 Westminster
Forum, ‘The future of the life sciences sector in the UK’ and have been approved by the speakers
2 6 | U K S PA B R E A K T H R O U G H | S u m m er 2 0 17
“One of the big challenges,
if you talk to Greg Clark
about the industrial
strategy, is summed up
by the question ‘What
are you going to do
about Grimsby?’ We need
to have narratives that
address the people that
have been forgotten.”
Professor Sir Robert Lechler PMedSci
President, Academy of Medical
Sciences, and Executive Director,
King’s Health Partners
“I think we have
to put ourselves
on the other side
of the fence and
ask what are we
offering? Why
are we there?
Why would you
say yes to this
demand?”
Dr Martin Szomszor,
Consultant Data Scientist,
Digital Science